(Información remitida por la empresa firmante)
Bioretec is?developing?the new RemeOs™?product line?based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOs™ implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on?value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, CE-mark is expected to be received during 2023. Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical bone fracture treatment. Better Healing – Better Life. www.bioretec.com
Appendix
Bioretec Ltd half year report January – June 2023 (PDF)
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/bioretec-ltds-half-year-report-2023-unaudited-historic-achievement-supported-by-the-strong-sales-301898570.html